Compare IQV & AFRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | AFRM |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 28.3B |
| IPO Year | 2013 | 2020 |
| Metric | IQV | AFRM |
|---|---|---|
| Price | $247.64 | $70.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 25 |
| Target Price | ★ $227.13 | $84.52 |
| AVG Volume (30 Days) | 1.3M | ★ 3.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.67 | ★ 108.98 |
| EPS | ★ 1.61 | 0.90 |
| Revenue | ★ $9,739,000,000.00 | $3,224,412,000.00 |
| Revenue This Year | $6.77 | $30.78 |
| Revenue Next Year | $5.89 | $23.95 |
| P/E Ratio | $151.84 | ★ $80.69 |
| Revenue Growth | ★ 41.60 | 38.80 |
| 52 Week Low | $154.50 | $42.10 |
| 52 Week High | $247.72 | $100.00 |
| Indicator | IQV | AFRM |
|---|---|---|
| Relative Strength Index (RSI) | 80.75 | 40.18 |
| Support Level | $159.91 | $66.21 |
| Resistance Level | N/A | $79.10 |
| Average True Range (ATR) | 6.70 | 2.94 |
| MACD | 3.10 | -1.43 |
| Stochastic Oscillator | 92.37 | 7.16 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Founded in 2012, Affirm is a market leader in the buy now, pay later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also constitute the majority of its revenue. Affirm primarily operates in the United States, which accounted for more than 95% of its revenue in 2025, but it has also expanded to Canada and the United Kingdom.